Merck reported a strong set of Q2 figures, helped at the profitability line by some positive one-offs. The drivers for the individual divisions were as expected (Healthcare: organic growth from General Medicine and new drugs; Life Science: strong demand for single-use products). Performance Materials proved more resilient than expected (OLED). Merck’s Q2 figures were above our cautious expectations and also beat the consensus.
08 Aug 2019
Good profitable development with some toppings
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good profitable development with some toppings
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
08 Aug 2019 -
Author:
Martin Schnee -
Pages:
3
Merck reported a strong set of Q2 figures, helped at the profitability line by some positive one-offs. The drivers for the individual divisions were as expected (Healthcare: organic growth from General Medicine and new drugs; Life Science: strong demand for single-use products). Performance Materials proved more resilient than expected (OLED). Merck’s Q2 figures were above our cautious expectations and also beat the consensus.